pharmaphorum July 28, 2021

Advances in cell and gene science are paving the way for transformative cancer treatments, but there are still many complexities in delivering clinical trials for these therapies. ICON’s Tamie Joeckel and Brandon Fletcher take us through best-practice approaches to CGT studies and discuss what the future could hold for this exciting area.

Cell and gene therapies (CGTs) might be showing amazing promise in tackling cancers that were previously thought almost-untreatable, but their novelty and complexity mean the industry is still working out how best to run trials for these therapies – which have some key differences from ‘traditional’ studies.

ICON was one of the first CROs of scale...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, Pharma / Biotech
Venture firms warn R&D funding for new drugs will 'drop off a cliff' if Dem bill approved
Contentious report suggests safety net hospitals leveraging discounts to pocket strong gains from cancer drugs
Adrian Cheng Moves Deeper Into Healthcare Industry With Artisan Merger Of Prenetics At $1.2 Bln Valuation
Complexities of COVID-19 manufacturing
340B hospitals mark up cancer drugs 3.8X for commercially insured patients, study finds